ALK mutation dynamics and clonal evolution in a neuroblastoma model exhibiting two ALK mutations

Simon Durand,Cécile Pierre-Eugène,Olivier Mirabeau,Caroline Louis-Brennetot,Valérie Combaret,Léo Colmet-Daage,Orphée Blanchard,Angela Bellini,Estelle Daudigeos-Dubus,Virginie Raynal,Gudrun Schleiermacher,Sylvain Baulande,Olivier Delattre,Isabelle Janoueix-Lerosey

DOI: https://doi.org/10.18632/oncotarget.27119

2019-08-13

Oncotarget

Abstract:The <i>ALK</i> gene is a major oncogene of neuroblastoma cases exhibiting ALK activating mutations. Here, we characterized two neuroblastoma cell lines established from a stage 4 patient at diagnosis either from the primary tumor (PT) or from the bone marrow (BM). Both cell lines exhibited similar genomic profiles. All cells in the BM-derived cell line exhibited an ALK F1174L mutation, whereas this mutation was present in only 5% of the cells in the earliest passages of the PT-derived cell line. The BM-derived cell line presented with a higher proliferation rate <i>in vitro</i> and injections in Nude mice resulted in tumor formation only for the BM-derived cell line. Next, we observed that the F1174L mutation frequency in the PT-derived cell line increased with successive passages. Further Whole Exome Sequencing revealed a second ALK mutation, L1196M, in this cell line. Digital droplet PCR documented that the allele fractions of both mutations changed upon passages, and that the F1174L mutation reached 50% in late passages, indicating clonal evolution. <i>In vitro</i> treatment of the PT-derived cell line exhibiting the F1174L and L1196M mutations with the alectinib inhibitor resulted in an enrichment of the L1196M mutation. Using xenografts, we documented a better efficacy of alectinib compared to crizotinib on tumor growth and an enrichment of the L1196M mutation at the end of both treatments. Finally, single-cell RNA-seq analysis was consistent with both mutations resulting in ALK activation. Altogether, this study provides novel insights into ALK mutation dynamics in a neuroblastoma model harbouring two ALK mutations.